IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud
IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud
IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.
Building on the IQVIA Orchestrated Customer Engagement (OCE) platform, launched in 2017, the partnership will apply innovations from IQVIA OCE with Salesforce’s Life Sciences Cloud to provide customers with a new single, end-to-end engagement platform. Salesforce’s leading CRM software, powered by IQVIA data, domain expertise and advanced analytics, is expected to transform healthcare professional (HCP) and patient engagement.
As part of the expanded partnership, IQVIA will license the OCE CRM related software to Salesforce, and the parties will collaborate to accelerate development of Life Sciences Cloud for customer engagement, expected to be available in 2025*. IQVIA will continue to market the OCE CRM product and will support its nearly 400 global OCE customers in 130+ countries through 2029. IQVIA will work with Salesforce to jointly market the new offering. The two companies will bring together talent, technology and expertise to ensure a coordinated transition from IQVIA’s OCE to Salesforce’s next generation life sciences solution.
“Our expanded relationship with Salesforce will bring the best of our combined capabilities in data, AI and technology to life sciences customers. In collaboration with various strategic partners across multiple healthcare verticals, IQVIA will continue to develop innovative technology solutions to help accelerate decision making across discovery, clinical development, medical affairs, real world evidence generation, patient safety, regulatory compliance, patient engagement and commercial operations,” said Bernd Haas, SVP and Head of Digital Products and Solutions at IQVIA.
“Our collaboration with IQVIA marks a pivotal moment for Salesforce Life Sciences Cloud innovation. It will transform the future of HCP engagement, bringing together our combined capabilities in CRM, AI, data, and the thought leadership of IQVIA, all on the trusted Einstein 1 Platform,” said Frank Defesche, SVP and General Manager, Life Sciences at Salesforce. “This collaboration will provide life science organizations with a single, intelligent end-to-end engagement platform to transform the customer experience to be orchestrated and personalized.”
*While Life Sciences Cloud launches June 2024, Sales automation functions for pharma/biotech customers are currently not offered for sale by Salesforce and will not be available for sale by Salesforce until after September 1, 2025. Commercial functions for medical technology customers are generally available today.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources, extensive domain expertise and network of partners. IQVIA Connected Intelligence™ delivers actionable insights and powerful solutions with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
About Salesforce
Salesforce is the #1 AI CRM, empowering companies to connect with their customers in a whole new way through the power of CRM + AI + Data + Trust on one unified platform: Einstein 1. For more information visit: www.salesforce.com (NYSE: CRM).
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.610.244.3020
Trent Brown, IQVIA Media Relations (trent.brown@iqvia.com)
+1.919.780.3221
Sarah Kennedy, Salesforce Media Relations (sarah.kennedy@salesforce.com)
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408191421/en/
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now